Podcasts about Stratification

Send us a textIn this episode we meet John Lynch, founder of Context Studio based in Dublin, Ireland. John's career path has taken him from countries where design is part of everyone's mindset, to places where some businesses have yet to see the full value that design can bring.  He shares the approaches that he's used to gain traction and make the case for adopting Service Design and stories of how design-led approaches have helped his teams to engage diverse stakeholder groups and generate better service outcomes.We talk about the privilege of working with public sector folks, who's vocation is to make society better... and we talk of the impact of "better" vs. "new" and why Renovate often delivers more than Innovate when it comes to Service Design.About John.John Lynch is founder and director of Context Studio, a service design studio in Dublin, and a voluntary board director at the Institute of Designers in Ireland. With a background in software development, John is a committed advocate of design in the service of the public good.References from John's episode.Stratification of Design Thinking  -Stefanie Di RussoDanish Design LadderDark Matter and Trojan Horses  -Dan HillJohn Heskett Ireland's Action Plan for Designing Better Public Services.Service Design YAP is developed and produced by the Service Design Network UK Chapter.Its aim is to engage and connect the wider Service Design community. Episode Host: Stephen Wood Production Assistance: Jean Watanya

Darrick Hamilton, director of the Institute for the Study of Race, Stratification, and Political Economy at the New School talks about Trump's Platinum Plan and whether it was a bait and switch move on Black America. Become a supporter of this podcast: https://www.spreaker.com/podcast/tavis-smiley--6286410/support.

The JournalFeed podcast for the week of April 21-25, 2025.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Wednesday Spoon Feed:This preplanned subgroup analysis of the TOMAHAWK Trial of patients with ROSC after OHCA found no EKG findings (excluding STEMI) that predicted the presence of coronary artery lesions.Thursday Spoon Feed:In this substudy of the Canadian TIA Score cohort, researchers found score utilization with subsequent MRI imaging could improve the outcome of patients suffering from TIA or stroke, particularly in the medium-risk category, scoring between 4-8 points.

Commentary by Dr. Xinxin Zhang.

How do you predict which intermediate-risk patients will suddenly deteriorate? What role do risk scores, biomarkers, imaging, and hemodynamics play in decision-making? Should these patients receive anticoagulation alone, or is thrombolysis warranted? When should you consider catheter-directed or surgical interventions? This podcast focuses us to think critically about risk stratification, early interventions and escalation in care in PE. We include an algorithm in the show notes. Not all patients fit neatly into classification boxes, making clinical judgment crucial. Join Dr. Lauren Westafer, Dr. Justin Morgenstern, Dr. Bourke Tillman and Anton as they explore the key decision points, pitfalls, and lifesaving strategies for managing intermediate-risk PE in the ED...

Derek Hall, chairman of the Sheep Stratification Group, joins us to talk about the strategy in place to strengthen the native UK sheep breeds. We hope you enjoy, Cammy & Iona Send in a question for the podcast: podcast@fedbyfarmers.co.uk Thanks to our Sponsors: Crystalyx Herdwatch: https://herdwatchng.app.link/FedbyFarmers You Can Support the show here: Buy us a coffee - https://www.buymeacoffee.com/fedbyfarmers Visit our website to see our range of custom made clothing www.fedbyfarmers.co.uk Our podcast releases on Audio platforms at 7am, and on youtube later the same day.

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar,... The post Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! appeared first on VJHemOnc.

Every civilization is shaped by its ruling elite, but what happens when those planning your society cannot understand the average person? Authors Charles Murray and Christopher Lasch have both discussed the dangers of cognitive stratification and how it could destroy social fabric. We will be discussing how that problem recently manifested itself in the debate over immigration and employment. Follow on: Apple: https://podcasts.apple.com/us/podcast/the-auron-macintyre-show/id1657770114 Spotify: https://open.spotify.com/show/3S6z4LBs8Fi7COupy7YYuM?si=4d9662cb34d148af Substack: https://auronmacintyre.substack.com/ Twitter: https://twitter.com/AuronMacintyre Gab: https://gab.com/AuronMacIntyre YouTube:https://www.youtube.com/c/AuronMacIntyre Rumble: https://rumble.com/c/c-390155 Odysee: https://odysee.com/@AuronMacIntyre:f Instagram: https://www.instagram.com/auronmacintyre/ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Dr. Valentin Fuster discusses a groundbreaking study on using artificial intelligence (AI) in electrocardiograms (ECGs) to assess left ventricular diastolic function and predict outcomes in patients with significant mitral regurgitation. The study demonstrates that AI-driven ECGs can offer comparable prognostic value to traditional echocardiography, identifying high-risk patients and potentially revolutionizing cardiovascular diagnostics, though challenges around sensitivity, specificity, and patient selection remain.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on coronary artery calcium for risk stratification among persons with very high HDL cholesterol.

On this episode of the Strip-Till Farmer podcast, brought to you by Yetter, University of Illinois soil scientist Andrew Margenot shares key takeaways from his long-term phosphorous (P) studies. Margenot's research group focuses on everything from NPK recommended rates, soil test values, removal rates and more. He's currently leading the charge on a project to analyze thousands of soil samples dating back to the late 1800s — the largest soil samples archive in the world.

CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.=

Darrick Hamilton, director of the Institute for the Study of Race, Stratification, and Political Economy at the New School, gives a deep-dive analysis into the competing economic plans in this year's presidential election and an update on the state of our economy.

In this week's episode we'll learn about refining risk stratification in T-cell acute lymphoblastic leukemia, or ALL. After that, we'll discuss a novel gene therapy approach in severe alpha-thalassemia. Investigators describe an innovative mouse model and an effective gene therapy approach, renewing prospects for the development of novel strategies to treat this disease. Finally, we'll hear about how genomic profiling has helped identify subgroups associated with distinct clinical phenotypes and outcomes in the molecular taxonomy of myelodysplastic syndromes, or MDS. Featured Articles NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup ofpatientsUse of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviralgene therapyMolecular taxonomy of myelodysplastic syndromes and its clinical implications

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that evaluates the role of myocardial fibrosis in predicting sudden cardiac death and ventricular arrhythmias in patients with non-ischemic cardiomyopathy. The findings suggest that assessing fibrosis through advanced imaging techniques offers a more accurate risk stratification than the traditional reliance on left ventricular ejection fraction, ultimately refining treatment approaches for at-risk patients.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on mortality risk stratification utilizing artificial intelligence electrocardiogram for hyperkalemia in cardiac ICU Patients.

In this week's episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - A review of what to look at on the bone marrow biopsy report - WHO and ICC classification for AML and MDS - Disease-defining cytogenetic markers to be aware of and their prognostic implications ****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, we delve into the world of social protection with one of its foremost experts, Professor Armando Barrientos, Emeritus Professor of Poverty and Social Justice at the Global Development Institute, University of Manchester. We discuss his groundbreaking new book, Social Protection in Latin America, and explore the argument that social protection systems or institutions are not just safety nets but also mechanisms of stratification. We also talked about what that means, why it matters, and how it shapes the lives of millions across the region. Finally, we also examine the crucial role of politics in shaping social protection and debate whether Latin America should aspire to the European model of a welfare state. From the Latin American innovative approaches to their global influence and the future of social protection, this episode is a must-listen for anyone interested in the intersection of social justice and public policy.   Episode resources: Book | Social Protection in Latin America. Causality, Stratification and Outcomes Task Force | Global Alliance against Poverty and Hunger Publication | The relationship between cash-based interventions and violence: A systematic review and evidence map

durée : 00:45:09 - La 20e heure - par : Eva Bester - Eva Jospin, l'artiste aux forêts immenses ciselées minutieusement dans du carton, décline son travail de la sculpture à la broderie et présente une chambre à soi en soie dans l'orangerie du Château de Versailles, et son univers sylvestre au Museo Fortuny, dans le cadre de la Biennale de Venise.

Deena Mohamed fait partie de la nouvelle garde de la bande dessinée égyptienne. Installée au Caire, elle dessine depuis son enfance. En 2013, à 18 ans, elle publie son premier ouvrage, Qahera, dans le sillage de la révolution égyptienne. Elle y mettait en scène une super-héroïne musulmane qui combat les codes, les traditions, les propos intégristes et misogynes. Cette année, la dessinatrice égyptienne revient avec une nouvelle bande dessinée, Shubeik Lubeik, littéralement « Vos désirs sont des ordres », qui vient d'être traduite en français. L'autrice est au micro de RFI. ► Les trois tomes de Shubeik Lubeik, compilés en un exemplaire et traduit en langue française, sont à retrouver en libraire aux éditions Steinkis, 2024.

We over-admit low risk acute heart failure patients and under-admit high risk heart failure patients. In this podcast we discuss the diagnostic accuracy of various clinical features, lab tests and imaging modalities for acute heart failure, the 3 validated risk stratification tools and a simple approach to PoCUS for the diagnosis and prognostication of acute heart failure in the ED to improve our diagnostic accuracy and disposition decisions for patients with acute heart failure...

CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-in-newly-diagnosed-cll/26494/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Listen to hear our expert panel discuss risk stratification beyond the current guidelines. Topics include normotensive shock, a perspective from radiology, the NEWS Score, and VTI. Faculty discuss interesting cases and address challenging questions regarding how to risk stratify.

Dr. Neeraj Agarwal and Dr. Rana McKay discuss promising studies in GU cancers featured at the 2024 ASCO Annual Meeting that highlighted improved outcomes in urothelial carcinoma, improved survival in renal cell carcinoma, and the role of ctDNA as a potential biomarker for predicting outcomes.   TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News.  I am delighted to welcome Dr. Rana McKay, a GU medical oncologist and associate professor at the University of California San Diego. Today, we'll be discussing some key GU abstracts featured at the 2024 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Rana, we're thrilled to have you on the podcast today to share your insights on key advances in GU oncology from ASCO24. Dr. Rana McKay: Thank you so much, Neeraj; it's a pleasure to be here. Dr. Neeraj Agarwal: So, Rana, let's start with some bladder cancer abstracts. Could you tell us about Abstract 4503, titled “Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer”? Dr. Rana McKay: Of course, I would be delighted to. First, I would like to remind our listeners that enfortumab vedotin (EV) was approved as a monotherapy for the treatment of locally advanced or metastatic urothelial cancer based on the results of EV-201 and EV-301 trials. In these pivotal studies, EV was initiated at a dose of 1.25 mg/kg, and dose modifications, such as reductions and interruptions, were used to manage adverse events. In the abstract presented at ASCO 2024, Dr. Daniel Petrylak and colleagues conducted a post-hoc exploratory analysis to evaluate the association between EV plasma exposure and outcomes. They used multiple pharmacokinetic samples collected during the first two cycles and pre-dose samples from 3 EV monotherapy studies, namely EV-101, EV-201, and EV-301, that were conducted in patients with previously treated locally advanced or metastatic urothelial carcinoma. Dose reductions to 1 mg/kg were required in 42.1% and 35.1% of patients in the EV-201 and EV-301 trials, respectively, and reductions to 0.75 mg/kg were required in 13.6% and 11.1% in the EV-201 and EV-301 trials, respectively. Higher EV exposure during the first two cycles was associated with a higher objective response rate. The ORR was 21.4% for the dose of 0.75 mg/kg, while it was 18.5% for the dose of 1.0 mg/kg. Interestingly, increasing the dosage to 1.25 mg/kg improved the ORR, which ranged from 40 to 51.1% across various studies. In the EV-301 trial, when comparing the efficacy of EV to chemotherapy, EV improved PFS and OS across all dose quartiles, and there was no evidence that recommended dose modifications impacted long-term efficacy outcomes. Dr. Neeraj Agarwal: Thank you, Rana, for this great summary. I would like to add that the meticulously conducted pharmacokinetic studies demonstrated that serum levels of EV correlated with responses. Importantly, patients who had to decrease the dose did not experience compromised outcomes as EV improved PFS and OS outcomes vs chemotherapy in across all exposure quartiles in the EV-301 trial where EV was compared with chemotherapy. These findings highlight the need to start at the recommended dose of 1.25 mg/kg and reduce it, if necessary, however, clinicians should not start at a lower dose.  Dr. Rana McKay: I totally agree with you, Neeraj. Now, moving on to a different setting in bladder cancer, what can you tell us about LBA4517, titled “Perioperative sacituzumab govitecan alone or in combination with pembrolizumab for patients with muscle-invasive urothelial bladder cancer: SURE-01/02 interim results”? Dr. Neeraj Agarwal: Of course! So, SURE was a multicohort, open-label, phase 2 study in patients with muscle-invasive bladder cancer assessing sacituzumab govitecan as a neoadjuvant therapy either alone in SURE-01 or as a combination with pembrolizumab followed by adjuvant pembro in SURE-02 in a flexible design allowing a bladder-sparing approach. In the abstract presented at ASCO 2024, Dr. Antonio Cigliola and colleagues report interim results of the SURE-01 study. Patients with cT2-4N0M0 urothelial carcinoma who were ineligible for or refused cisplatin-based neoadjuvant chemotherapy were planned to receive 4 cycles of neoadjuvant sacituzumab govitecan at a dose of 10 mg/kg followed by radical cystectomy.  An extensive assessment was performed at baseline and after the 4 cycles for response assessment. Patients with clinical complete response defined with negative MRI, cystoscopy and ctDNA assays refusing radical cystectomy were offered redo transurethral resection of the bladder tumor or repeat TURBT followed by observation in the absence of viable high-grade tumor in the bladder. The primary endpoint was pathological complete response rate, while secondary endpoints included pathological downstaging rate and safety. After the first 8 patients were enrolled, the protocol was amended due to the occurrence of grade 3 and 4 neutropenia and diarrhea in 75% and 50% of patients, respectively, and 2 deaths – one of which was deemed to be treatment-related due to sepsis. Key protocol changes included the reduction of the dose of sacituzumab govitecan to 7.5 mg/kg, the introduction of G-CSF as primary prophylaxis, and the exclusion of patients at high risk of febrile neutropenia per ASCO guidelines.  Among 21 patients who received at least one cycle of sacituzumab govitecan and included in the intention-to-treat population, 47.6% had a complete pathological response, and 52.4% had pathological downstaging. 11 patients underwent radical cystectomy, while 7 received repeat-TURBT due to complete clinical response or patient preference. Regarding the safety profile, grade 3 or more adverse events occurred in 42.5% of patients. Treatment-related adverse events leading to dose interruptions or discontinuations were more common before the protocol amendment. It is noteworthy that 3 patients died after treatment discontinuation, with one deemed treatment-related, as previously mentioned. Dr. Rana McKay: Thank you, Neeraj, for a great summary. The pathological complete responses observed show promising activity for sacituzumab govitecan as a neo-adjuvant therapy and a window for bladder-sparing approaches, which is definitely exciting news for our patients! However, although the 3 deaths encountered in a neo-adjuvant setting could be concerning, the improvement of the safety profile after protocol amendments is reassuring and supports the continuation of the study. Dr. Neeraj Agarwal: Before wrapping up the bladder cancer section, would you like to share your insights with our listeners on Abstract 4518, titled “Quantitative circulating tumor DNA (ctDNA) assessment in patients with advanced urothelial carcinoma treated with pembrolizumab or platinum-based chemotherapy from the phase 3 KEYNOTE-361 trial”?  Dr. Rana McKay: Sure. So, the KEYNOTE-361 trial was a randomized phase 3 study with 3 arms that included pembrolizumab plus chemotherapy, pembrolizumab monotherapy, or chemotherapy alone in patients with previously untreated advanced urothelial carcinoma. The results showed that neither the combination of pembrolizumab plus chemotherapy nor pembrolizumab monotherapy improved survival outcomes compared to the chemotherapy arm. So, in this exploratory analysis presented at ASCO24, Dr. Tom Powles and colleagues sought to assess the role of ctDNA as a potential biomarker between the pembrolizumab monotherapy arm and the chemotherapy arm. Tumor tissue mutations were evaluated using whole exome sequencing, and plasma ctDNA was assessed with the Guardant 360 assay. Changes in ctDNA from pre-treatment cycle 1 to on-treatment cycle 2, so 3 weeks post-baseline assessment, were quantified by the maximum variant allele frequency of tumor tissue-specific mutations.  Results showed that lower baseline ctDNA levels were associated with improved clinical outcomes of response in the pembrolizumab arm but not in the chemotherapy arm. This improvement in the pembrolizumab arm was also robust to adjustment for tumor mutational burden and PD-L1. Additionally, chemotherapy led to a ctDNA clearance rate of 41% compared to 11% in the pembrolizumab arm. Patients who had a large ctDNA reduction with pembrolizumab had significantly improved outcomes compared to those achieving a large reduction with chemotherapy with a hazard ratio of 0.25. However, this did not replicate in patients who did not achieve a large reduction, as these patients had similar outcomes across both arms. Let's switch gears to kidney cancer and start with Abstract 4508, reporting the final OS analysis from the JAVELIN Renal-101 trial. Neeraj, what would you like to tell us about this abstract? Dr. Neeraj Agarwal:  Well, as a quick reminder, the JAVELIN Renal-101 was a randomized phase 3 trial where patients with previously untreated advanced or metastatic clear cell renal cell carcinoma were randomized to receive either the combination of avelumab plus axitinib or sunitinib. In previous analyses, the combination of avelumab and axitinib significantly improved PFS compared to sunitinib and was subsequently approved by the FDA for the first-line treatment of patients with advanced RCC in 2019. This superiority in PFS was maintained across the different analyses; however, OS data remained immature. In the abstract presented at ASCO24 by Dr. Robert Motzer from Memorial Sloan Kettering Cancer Center and colleagues, the authors reported OS results at a median follow-up of around 73 months and a minimum of 68 months for all patients, which is the longest follow-up for any ICI-TKI combination in RCC. The final analysis in the overall population favored the combination of avelumab plus axitinib with a median OS of 44.8 months compared to 38.9 months with sunitinib, however, this did not reach statistical significance with a hazard ratio of 0.88. The PFS results and safety profile were consistent with previous analyses.  Dr. Rana McKay: Thank you, Neeraj, for such a nice overview of this abstract. These new data could make this regimen less optimal than other ICI-TKI combinations in the first-line mRCC setting.   Dr. Neeraj Agarwal: I concur, Rana. Moving on to perhaps one of the most exciting GU abstracts featured, Abstract 4506, titled “Circulating kidney injury molecule-1 biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection.” Rana, what are your thoughts on this abstract? Dr. Rana McKay: Well, first, I would like to take a step back and remind our audience that in the IMmotion010 trial, patients with resected intermediate to high-risk RCC with clear cell and/or sarcomatoid component were randomized in a 1:1 ratio to receive either atezolizumab or placebo. Investigator-assessed disease-free survival, which was the primary endpoint, favored the atezolizumab arm but did not reach statistical significance. In the abstract featured at ASCO24, Dr. Laurence Albiges and colleagues build on data previously reported in the ASSURE and CheckMate 914 trials and report provocative findings regarding a molecule known as kidney injury molecule 1 or KIM-1, which is a type 1 membrane glycoprotein that has been identified as a minimally invasive potential peripheral blood circulating biomarker. The KIM-1 level of 86 pg/ml was identified as the optimized threshold for defining post-nephrectomy KIM-1 high vs KIM-1 low subgroups in the IMmotion010 trial. KIM-1 levels were measured at baseline or pre-treatment, at cycle 4 day 1, and at disease recurrence or discontinuation without disease recurrence. Baseline characteristics were balanced between the KIM-1 high and KIM-1 low groups, except perhaps for a slightly higher pathological stage in the KIM-1 high subgroup.  I would like to highlight 3 key takeaways from this abstract. First, KIM-1 high level was associated with significantly worse DFS with a hazard ratio of 1.75. Second, patients in the KIM-1 high subgroup receiving atezolizumab had a 28% reduction in the risk of recurrence or death compared to those receiving placebo, while those in the KIM-1 low subgroup had comparable outcomes across both treatment arms. Third, patients in the KIM-1 high subgroup receiving atezolizumab were significantly less likely to experience an on-treatment increase in KIM-1 levels, which was associated with worse DFS in both high and low KIM-1 subgroups, regardless of treatment arm. Thus, these findings support the use of KIM-1 as both a predictive and prognostic biomarker in patients with RCC. Dr. Neeraj Agarwal: Yes, Rana, this is amazing data! I would like to add that these results warrant larger and, ideally, prospective studies to validate the utility of KIM-1 as a noninvasive biomarker for identifying minimal residual disease after nephrectomy and for predicting outcomes to immune checkpoint inhibitors. Dr. Rana McKay: Also, in the field of biomarkers, 2 abstracts interrogating different biomarkers in a different setting, so in patients with advanced or metastatic RCC were presented. Neeraj, could you tell us more about these abstracts? Dr. Neeraj Agarwal: Of course! I think you are referring to Abstracts 4504 and 4505. In abstract 4504, Dr. Toni Choueiri and colleagues sought to assess the clinical implications of different biomarkers in the CLEAR trial, which was a randomized phase 3 trial that led to the approval of the combination of pembrolizumab plus lenvatinib in the first-line mRCC setting. On the other hand, in abstract 4505, Dr. Brian Rini presented biomarker results in KEYNOTE-426, which was also a randomized phase 3 trial based on which the combination of pembrolizumab plus axitinib was approved in patients with mRCC. The authors in both trials sought to investigate the role of biomarkers in predicting treatment outcomes from 3 different angles. Starting with PD-L1 expression, the superiority of the combination arms over sunitinib was not impacted by PD-L1 status in both trials. Moving on to RCC driver gene mutations on whole exome sequencing, such as VHL, SETD2, PBRM1, and BAP1, ICI combination therapies improved outcomes regardless of mutation gene status, and this improvement was statistically significant with PBRM1 mutations in KEYNOTE-426 compared to wild-type PBRM1, but this did not replicate in the CLEAR trial. Finally, using transcriptomic signatures derived from RCC trials, especially the IMmotion 151 and JAVELIN Renal 101 trials, where 7 clusters or molecular subtypes were identified, the combination arms outperformed sunitinib in all clusters in both trials and the magnitude of this benefit differed across clusters.  Dr. Rana McKay: Thank you for this very interesting summary and comparison of the results of these 2 abstracts. These findings support the use of ICI-based combinations in all patients with mRCC as a first-line option. Although these abstracts could not identify specific biomarkers that could guide us clinicians in treatment selection, they provide very interesting biological insights on these molecular biomarkers that are, however, not yet clinically actionable. Dr. Neeraj Agarwal: Very interesting point, Rana. Moving on to prostate cancer, let's start with abstract LBA5000 titled, “Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).” Rana, what is your takeaway on this abstract? Dr. Rana McKay: As a reminder to our audience, the CHAARTED2 trial was a randomized open-label phase 2 study that compared the combination of cabazitaxel and abiraterone to abiraterone alone in patients with mCRPC previously treated with ADT plus docetaxel in the hormone-sensitive setting. The primary endpoint was progression-free survival. After a median follow-up of 47.3 months, Dr. Christos Kyriakopoulos and colleagues reported in LBA5000 that patients receiving the combination of cabazitaxel plus abiraterone had a 27% reduction in the risk of progression or death. However, there was no significant difference in overall survival between the two arms, with a median OS of 25 months in the cabazitaxel+abiraterone arm and 26.9 months in the abiraterone arm, although the study was underpowered for this endpoint. Regarding the toxicity profile, the combination of cabazitaxel and abiraterone was overall well tolerated with more cytopenias, as expected.  Dr. Neeraj Agarwal: Very nice summary of this abstract, Rana. I would like to add that the treatment landscape of patients with mHSPC has evolved since the design of the study and now includes combination therapies of ADT + ARPI with or without docetaxel, and ADT + docetaxel is no longer a standard of care, which limits the applicability of these results in clinical practice today.  Dr. Rana McKay: Excellent point, Neeraj. Let's discuss Abstract 5001, titled “CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer”. Dr. Neeraj Agarwal: Sure! In the abstract featured at ASCO24, Dr. Matthew Smith and colleagues report the primary results of the CYCLONE 2 trial, which was a randomized phase 2/3 study that investigated the combination of abemaciclib plus abiraterone versus abiraterone monotherapy in patients with mCRPC. Stratification factors included radiographic progression at study entry, presence of measurable disease, and prior docetaxel for mHSPC. Part 1 of the study established the recommended phase 2 dose of abemaciclib at 200 mg twice daily. In part 2, patients were randomized to placebo or abemaciclib, and an adaptive interim analysis using prespecified criteria was performed and recommended the expansion of the study to part 3. The primary endpoint was investigator-assessed radiographic progression-free survival by RECIST 1.1 and PCWG3 criteria in the intention-to-treat population. At the time of the primary analysis, adding abemaciclib to abiraterone did not improve rPFS, with a hazard ratio of 0.83. The median rPFS was 22 months for the combination arm and 20.3 months for the abiraterone arm. The combination was well tolerated, and the safety profile was consistent with the known adverse events. Dr. Rana McKay: So, the addition of abemaciclib to abiraterone did not improve outcomes in patients with mCRPC. These findings suggest that no further investigation is warranted for abemaciclib or CDK4/6 inhibitors in biomarker-unselected patients with prostate cancer.  Dr. Neeraj Agarwal: Rana, what's your take-home message on Abstract 5006, titled “Health-related quality of life results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer”? Dr. Rana McKay: So, as a reminder to our audience, the PRESTO trial was a randomized phase 3 study that assessed the effects of intensified androgen receptor blockade in patients with biochemically recurrent prostate cancer following local therapies. Patients with a PSA doubling time of less than 9 months and no evidence of metastatic disease were randomized to receive either 52 weeks of ADT alone, ADT plus apalutamide, or ADT plus apalutamide plus abiraterone. In their paper published earlier this year in the Journal of Clinical Oncology, the authors showed that patients receiving ADT plus apalutamide with or without abiraterone had significantly longer PSA-progression-free survival than those receiving ADT alone. In the oral presentation featured at ASCO24, Dr. Ronald Chen and colleagues report health-related quality of life outcomes that were assessed using various questionnaires or scales at baseline, at cycle 7, which is around 6 months on treatment, and at the end of treatment. Results showed that this intensified approach with apalutamide did not significantly increase severe adverse events, did not lengthen the time to testosterone recovery, and did not meaningfully increase common treatment-related symptoms such as hormonal symptoms, sexual dysfunction, hot flash interference, and fatigue. Importantly, additional intensification with abiraterone did not further improve PSA-PFS but did increase the rate of serious adverse events, lengthened the time to testosterone recovery, and increased hot flash interference.  Dr. Neeraj Agarwal: So, in conclusion, the PRESTO trial supports using intensified androgen blockade with apalutamide to improve PSA-PFS in patients with high-risk biochemically recurrent prostate cancer without compromising health-related quality of life. However, adding abiraterone did not offer additional benefits and increased side effects.  Dr. Rana McKay: Let's move on to LBA5002 titled, “A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.” Would you like to share your insights on this abstract with our listeners? Dr. Neeraj Agarwal: Absolutely. MAST was a randomized, double-blinded, placebo-controlled trial that investigated the impact of metformin on the progression of low-risk localized prostate cancer in patients choosing to undergo active surveillance. Eligible patients had biopsy-proven, low-risk, localized prostate cancer diagnosed within the past 6 months, characterized by a Gleason score of less than 6 observed in less than one-third of the total cores, less than 50% positivity in any one core, a PSA level of less than 10 ng/ml, and a clinical-stage between T1c and T2a. Patients were randomized in a 1:1 ratio to receive either metformin 850 mg twice daily or placebo for three years. All patients underwent repeat prostate biopsy at 18 and 36 months. The primary endpoint was time to progression, defined as the earliest occurrence of primary prostate cancer therapy, such as prostatectomy, radiation, hormonal therapy, or pathological progression on subsequent biopsies, which was defined as more than 1/3 of total cores involved, at least 50% of any one core involved, or Gleason pattern 4 or higher. The study included 407 patients, with 204 receiving metformin and 203 receiving a placebo. Results presented by Dr. Anthony Joshua showed no statistically significant difference in progression-free survival, including therapeutic and pathologic progression, with an unadjusted hazard ratio of 1.08.  Interestingly, there was a signal that patients with a BMI more than 30 had a detriment to taking metformin with a higher risk of progression compared to those receiving placebo with an unadjusted HR of 2.39 and a p-value of 0.01. Dr. Rana McKay: I would like to add that this study showed that metformin use does not prevent the progression of low-risk localized prostate cancer on active surveillance and could represent a potential detriment for patients with high BMI at study entry. Dr. Neeraj Agarwal: Yes, Rana, I concur. Any final remarks before we conclude today's podcast? Dr. Rana McKay:  Thank you, Neeraj; it's been wonderful being here with you today and you having me on the podcast to highlight these important advances and the amazing work that many investigators are conducting and the patients who were involved in the context of these trials. It's really excellent to see these updated results.   Dr. Neeraj Agarwal: Before we wrap up this podcast, I would like to say that we have reviewed a selection of abstracts addressing prostate, bladder, and kidney cancer, which are significantly impacting our medical practices now and in the near future. Rana, thank you for sharing your insights today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion. Many thanks. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Find out more about today's speakers:    Dr. Neeraj Agarwal   @neerajaiims   Dr. Rana McKay  @DrRanaMcKay     Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn         Disclosures:        Dr. Neeraj Agarwal:         Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences     Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas      Dr. Rana McKay:   Consulting or Advisory Role: Janssen, Novartis, Tempus, Exelxis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Pfizer, Bayer, Tempus

Interview with Albert S. Chiou, MD, MBA, author of Single-Lesion Skin Cancer Risk Stratification Triage Pathway. Hosted by Adewole Adamson, MD, MPP. Related Content: Single-Lesion Skin Cancer Risk Stratification Triage Pathway

Interview with Albert S. Chiou, MD, MBA, author of Single-Lesion Skin Cancer Risk Stratification Triage Pathway. Hosted by Adewole Adamson, MD, MPP. Related Content: Single-Lesion Skin Cancer Risk Stratification Triage Pathway

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.” In this new perspective, researchers Jai N. Patel, Jai Singh, and Nilanjan Ghosh from Atrium Health discuss Ibrutinib — the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL). “While producing durable responses and prolonging survival, roughly 20–25% of patients experience dose limiting side effects, mostly consisting of cardiovascular toxicities like severe hypertension and atrial fibrillation.” While clinical predictors of BTK inhibitor-related cardiotoxicity have been proposed and may aid in risk stratification, there is no routine risk model used in clinical practice today to identify patients at highest risk. A recent study investigating genetic predictors of ibrutinib-related cardiotoxicity found that single nucleotide polymorphisms in KCNQ1 and GATA4 were significantly associated with cardiotoxic events. If replicated in larger studies, these biomarkers may improve risk stratification in combination with clinical factors. “A clinicogenomic risk model may aid in identifying patients at highest risk of developing BTK inhibitor-related cardiotoxicity in which further risk mitigation strategies may be explored.” DOI - https://doi.org/10.18632/oncotarget.28589 Correspondence to - Nilanjan Ghosh - nilanjan.ghosh@atriumhealth.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28589 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, BTK inhibitor, cardiotoxicity, biomarkers, risk, genetics About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

For more information, visit IO360summit.com. 

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the... The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.

Commentary by Dr. Candice Silversides

Dr. Tarik Kani  interviews Dr Alberto Zanetto from Italy, on their study which they were created a new model to predict acute-on-chronic liver failure in decompensated cirrhosis.

Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study (AHA 2023)

A listener email sends us deep into the lakes of Latvia — and to honor victims of genocide, it's important to talk about what it is, how it happens and who it happens to.

Commentary by Dr. Bailey Estes and Dr. Philippe Pibarot

In this week's episode we'll discuss extended follow-up from the ZUMA-5 trial of axicabtagene ciloleucel, or axi-cel. Then we'll learn about the role of platelets in binding and clearing senescent red blood cells. Finally, we'll hear about a new risk stratification strategy for lymphomas of the central nervous system, or CNS. 

Distrust is based on experience – and there are many historical experiences that give rise to distrust among African-Americans of economic institutions in the United States, including the laws of the Jim Crow era and discrimination in hiring, lending, and access to education and health care. Trevon Logan discusses historical experiences, and the long shadow cast by them, in this EconoFact Chats episode.  Part of this discussion centers on the Green Book, published annually between 1936 and 1966, that offered guidance to Black travelers about public accommodations like restaurants and motels that they could patronize. Trevon's research analyzes how the locations of establishments listed in the Green Book correlate with the presence of anti-discriminatory laws, the educational and racial profiles of towns and cities, and the history of overt racist acts like lynchings in those places.    Trevon is a Hazel C. Youngberg Trustees Distinguished Professor of Economics at the Ohio State University. He is also the inaugural director of the National Bureau of Economic Research Working Group on Race and Stratification in the Economy. Note: This podcast was first published on 18th September, 2022.

Author Jose Loya discusses the article, "Ethno-Racial Stratification in the Refinanced Mortgage Market" published in the January 2023 issue of Sociology of Race and Ethnicity.

In this rebroadcast episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jenny Mueller and Bill Zammarrelli to discuss molecular classification and risk stratification in endometrial cancer. Jenny Mueller, MD, is a gynecologic oncologist and assistant attending in the department of surgery at Memorial Sloan Kettering Cancer Center. She leads the endometrial cancer research team at MSKCC with an emphasis on prospective, translational, and collaborative efforts within and across institutions. Bill Zammarrelli, MD, currently works as a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center. He is a commissioned officer in the US Army and completed his residency at Walter Reed National Military Medical Center. His current research focuses on the genetics of endometrial cancer.    Highlights: --PORTEC-1 and GOG-99 risk classifications are discordant for stage I grade 3 endometrioid endometrial carcinoma (EEC). --Stage I grade 3 EECs of CN-high molecular subtype have a worse 3-year progression-free survival compared to non-CN-high molecular subtypes. --Molecular classification in combination with clinicopathologic factors may provide improved prognostic information.

Learning Objectives:Promoting evidence-based cancer screening and prevention strategiesUnderstanding risk factors related to eligibility for lung cancer screeningIdentifying the key aspects of a successful lung cancer screening programRecognizing the ways in which technology can be leveraged for identifying patients eligible for lung cancer screeningSpeakers:Suchitra Pilli, MD, Pulmonary Medicine, Interventional Pulmonology, CHI Health Omaha NebraskaPanelists:Misho Hubka, MD, Thoracic Surgeon, Medical Director, Virginia Mason Cancer Center and head of Thoracic surgery programPeter Emanuel, MD, Vice President of Oncology, CommonSpirit Health Oncology Clinical InstituteJohn D. Chelico, MD, MA, FACP, FAMIA, System Chief Medical Information Officer

Mechanisms and Strategies to Manage Temperature Stratification in Brewery Vessels Special Guest: Travis Audet.

Data plays a critical role in helping build a more equitable society. As leaders and organizations across the country grapple with how to strategically invest in Black communities, having access to relevant data about wealth equity in the U.S. is essential. Unfortunately, that data is often out-of-date, inaccessible, not disaggregated by race, and not available at the local level.So, how can we work to reduce the gaps in racial wealth equity data?Supported by the Bloomberg Philanthropies' Greenwood Initiative, the Black Wealth Data Center works to remedy the problem of insufficient and inaccessible data on the topic of Black wealth. By making relevant data disaggregated by race available, the Black Wealth Data Center's Racial Wealth Equity Database empowers leaders to leverage the data necessary to develop and implement effective programs and policies to increase racial wealth equity.To celebrate the Black Wealth Data Center's recent one-year anniversary, Katherine Oliver sits down with Garnesha Ezediaro, who leads Bloomberg Philanthropies' Greenwood Initiative, Darrick Hamilton, the Founding Director of the Institute for the Study of Race, Stratification and Political Economy at the New School, and Lamar Gardere, the Executive Director at The Data Center of Southeast Louisiana and national recipient of the Black Wealth Data Center and National Neighborhood Indicator's Local Data and Engagement Grant Program, to discuss the importance of data in advancing racial wealth equity, the challenges faced by organizations that don't have access to data, and how the Black Wealth Data Center is helping provide decision-makers with data collection and accessibility.

Let's zoom in on a specific and very crucial stage of the ag carbon credit generation process - the role of soil stratification. First off, what is soil stratification or also referred to as “soil strata?” Well, here is a little preview: Soil stratification is the process of dividing farm or ranch land into different areas that represent similar soil organic carbon to efficiently sample soil with the most accurate results. What does stratification look like? And how is it related to the monitoring, reporting and verification of carbon credits? Does AI and remote sensing play a part? We cover all that and more in this episode with Tommy Pudil, Agoro Carbon's Geospatial Analyst. Tommy is a member of the science team. He is originally from eastern Iowa, and attended school at Creighton University in Nebraska, as well as Georgia Southern University in Georgia. During his time at both schools, he used remote sensing to measure the health of vegetation and map land cover using artificial intelligence and machine learning. Growing up in Iowa, farming has always been something that is important to Tommy, and he enjoys using his skills to help the mission here at Agoro Carbon Alliance. In his free time, Tommy likes to fish, hike, lift weights, and spend time with family and friends.  

Learning Objectives:-Promoting evidence-based cancer screening and prevention strategies-Discerning between patients with average, below average, and above average risk-Recognizing the differences between modalities available for colorectal cancer screeningSpeakers:-Devi Mukkai Krishnamurty, MBBS, Colorectal Surgery, General Surgery, CHI Health Omaha Nebraska-Ron Gagliano, MD, Colorectal Surgeon, Chair, Surgery DHMG, and Associate CMO for the Dignity Health Cancer Institute in PhoenixPanelist:Peter Emanuel, MD, Vice President of Oncology, CommonSpirit Health Oncology Clinical Institute

Buy a tee! https://www.10percenttrue.com/product-page/magnum-classic-teeSupport me with a coffee! https://www.buymeacoffee.com/10percenttrue Discussion on Discord: https://discord.gg/9vJ3hPYFQh0:00 intro1:16 Bodo - why F-15s were there6:20 intercepting Bear/Badger/Coot without a radar lock and why12:05 interesting intercepts 15:55 Naval Badgers a different challenge 16:44 “KGB Coot”18:00 Velocity Search vs TWS?20:10 SIGINT 25:25 levels of “co-operation” of the intercepted 31:25 no IRST, no loss?38:00 continued but a hostile witness!45:35 HOBS and associated tactics 54:40 MATRA story1:01:10 “Eagle Eye”1:10:15 defensive shortcomings1:15:20 Light Grey Aloofness/Ego-jet/Stratification of the community 1:35:05 AMRAAM the great equaliser1:38:30 to share the secrets of employment or not?1:45:15 Jekyll & Hyde?1:48:10 loose ends and YT comments questions including VMAX, can you trust the books? 2:04:00 callsign storySupport the show

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Chas, Christian, Rudy, and James come together to delve into a comprehensive conversation about the Prague Spring, a significant Czechoslovak reform movement. Their discussion begins by tracing the roots of Czechoslovak communism, recounting the post-World War II Communist ascension to power, and elaborating on the gradual and intricate reform drive that eventually culminated in Dubček's rise to leadership during the Prague Spring of 1968. Subsequently, they explore the ideologies championed by key reformists, analyze the factors that prompted the Soviet Union's intervention, and dissect the shortcomings of the USSR's intervention strategy. Lastly, the conversation concludes by dissecting the reformers' envisioned goals and actual accomplishments. Bibliography: G. Golan - Reform Rule in Czechoslovakia: The Dubcek Era 1968–1969 J. Krejčí - Social Change and Stratification in Postwar Czechoslovakia V. Kusin - The Intellectual Origins of the Prague Spring: The Development of Reformist Ideas in Czechoslovakia, 1956-1967 V. Kusin - From Dubcek to Charter 77: A Study of 'Normalization' in Czechoslovakia, 1968-1978 Z. Mlynář - Nightfrost in Prague: The end of humane socialism O. Šik - Czechoslovakia: The Bureaucratic Economy. I. Svitak - The Czechoslovak Experiment: 1968 - 1969 K. Williams - The Prague Spring and its Aftermath: Czechoslovak Politics, 1968-1970

In this episode we discuss Chapter 18 in the Modern Epidemiology (4th Ed) textbook focused on stratification and standardization with Dr. Rich MacLehose. We invited the illustrious Dr. MacLehose to be the guest for this chapter because it is one of the most important in the book, linking the theoretical concepts discussed in the early chapters with the advanced analytic techniques discussed in subsequent chapters. In this episode we cover topics such as standardization, stratification, pooling, the use and interpretation of relative and absolute effect estimates, and p-values to evaluate effect heterogeneity.

In this episode of Body Bags, hosts Joseph Scott Morgan and Dave Mack delve into the tragic and unsettling death of 17-year-old Tylee Ryan. They discuss Tylee's tumultuous family life, her struggle with pancreatitis, the discovery of her remains, the challenges forensic experts faced in determining the cause of death, and they provide insight into the methods and findings of the forensic anthropologist and pathologist.   Time-codes:  00:34 - Introduction to Tylee Ryan's tragic story and difficult life. 01:22 - Tylee's horrifying death and forensic pathologist insights. 03:26 - Tylee's body is discarded and attempts to cover up. 03:15 - The impact of Tylee's mother's multiple marriages on her life. 04:51 - Tylee's medical records reveal stress and anxiety. 06:20 - Explanation of pancreatitis and potential causes. 07:08 - Tylee's stressful family life and stepfather's murder. 08:14 - Tylee's resistance to her mother's manipulations. 09:22 - Lori Vallow's justification for Tylee's murder. 09:37 - Location of Tylee's remains on Chad Daybell's property. 11:41 - Stratification concept in the burn pile investigation. 12:42 - Discovery of Tylee's remains and difference in location from JJ's remains. 13:16 - Importance of multiple senses in an investigation. 15:00 - The crucial role of a forensic anthropologist at the scene. 16:33 - Difficulty in recovering Tylee's fragmented remains. 18:34 - Relationship between forensic pathologists and forensic anthropologists. 20:19 - Odor differences between bones and soft tissue decomposition. 21:00 - Dr. Christensen finds 100 bones of Tylee's remains. 21:13 - Difficulties in identifying specific causes of death for Tylee. 22:09 - Classification of Tylee's death as nonspecific homicidal trauma. 24:10 - Speculation on Tylee's skull fracture cause. 26:12 - Attempt to dismember Tylee's body. 27:48 - Challenges of rendering a body down through fire. 28:18 - Sharp force trauma on Tylee's left hip bone. 29:03 - Tools for dismemberment and potential trace evidence.See omnystudio.com/listener for privacy information.